National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: The incomplete story

Australasian Psychiatry

Volumn 21, Issue 5, 2013, Pages 442-445

  Hollingworth, Samantha ^a   Duhig, Michael ^b   Hall, Wayne ^b   Scott, James ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Adolescents; Antipsychotic; Children; Medication; Pharmacoepidemiology; Youth

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGE; ARTICLE; AUSTRALIA; CHILD; COMMUNITY CARE; DRUG UTILIZATION; FEMALE; GENDER; HUMAN; INFANT; JUVENILE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRESCRIPTION; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENTS; ANTIPSYCHOTIC; CHILDREN; MEDICATION; PHARMACOEPIDEMIOLOGY; YOUTH;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84889064851     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856213497809     Document Type: Article

References (22)

1. Ardizzone I, Nardecchia F, Marconi A, et al. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull 2010; 43: 45-66.
2. Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12: 593-605.
3. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebocontrolled study. Bipolar Disord 2009; 11: 687-700.
4. Zuddas A, Zanni R and Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 2011; 21: 600-620.
5. Kendall T. The rise and fall of the atypical antipsychotics. Br J Psychiatry 2011; 199: 266-268.
6. Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010; 49: 583-594; quiz 632.
7. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res 2011; 45: 763-769.
8. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and secondgeneration antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-1431.
9. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-685.
10. Aparasu RR and Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 2007; 23: 49-56.
11. Rani F, Murray ML, Byrne PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121: 1002-1009.
12. Australian Government Department of Health and Ageing. Australian Statistics on Medicines 2008. Canberra: Department of Health and Ageing, 2009.
13. Hollingworth SA, Siskind DJ, Nissen LM, et al. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry 2010; 44: 372-377.
14. World Health Organisation. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc-ddd-index/(2008, accessed date 18 June 2008)
15. Australian Bureau of Statistics. Population by Age and Sex, Australian States and Territories. Cat. No. 3201.0. Australian Bureau of Statistics, 2008.
16. Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009; 19: 757-764.
17. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008; 2: 26.
18. Halloran DR, Swindle J, Takemoto SK, et al. Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics. Clin Pediatr (Phila) 2010; 49: 485-490.
19. Hollingworth SA, Nissen LM, Stathis SS, et al. Australian national trends in stimulant dispensing: 2002-2009. Aust N Z J Psychiatry 2011; 45: 332-336.
20. Nakamura Y, Ojima T, Oki I, et al. Estimation of the future numbers of patients with mental disorders in Japan based on the results of National Patient Surveys. J Epidemiol 1997; 7: 214-220.
21. Thomsen PH. Schizophrenia with childhood and adolescent onset - a nationwide register-based study. Acta Psychiatr Scand 1996; 94: 187-193.
22. Duhig MJ, Saha S and Scott JG. Efficacy of risperidone in children with disruptive behavioural disorders. J Paediatr Child Health 2013; 49: 19-26.